Lineage Cell Therapeutics, Inc.
LCTX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000876343
No open-market purchases or sales by Lineage Cell Therapeutics, Inc. insiders were filed in the last 90 days; 131 institutions reported holding it in 13F filings for Q2 2026, worth $152.7M in total; no superinvestor holds it.
Holders of 5% or more of LCTX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Lineage Cell Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Broadwood Partners, L.P. | 13D/A | 23.10%57.8M shares | −1.40 ppfrom 24.50% | Jan 28, 20252 filings | Nov 14, 2025 | SEC |
| Chernett Jorey | 13G | 5.00%11.4M shares | New | Sep 26, 20251 filing | Sep 26, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
6 Schedule 13D and 13G filings on Lineage Cell Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 14, 20256:12 PM ET | Broadwood Partners, L.P.and 2 others | 13D/A | 23.10%57.8M shares | −1.40 ppfrom 24.50% | Nov 12, 2025 | SEC |
| Sep 26, 202511:52 AM ET | Chernett Jorey | 13G | 5.00%11.4M shares | New | Sep 22, 2025 | SEC |
| Jul 17, 20257:54 PM ET | BlackRock, Inc. | 13G/A | 1.00%2.23M shares | −4.00 ppfrom 5.00%Below 5% | Jun 30, 2025 | SEC |
| Apr 24, 20258:48 AM ET | BlackRock, Inc. | 13G | 5.00%11.5M shares | +0.40 ppfrom 4.60% | Mar 31, 2025 | SEC |
| Feb 5, 20255:28 PM ET | BlackRock, Inc. | 13G/A | 4.60%10.1M shares | –Below 5% | Dec 31, 2024 | SEC |
| Jan 28, 20258:07 PM ET | Broadwood Partners, L.P.and 2 others | 13D/A | 24.50%57.8M shares | – | Jan 27, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Lineage Cell Therapeutics, Inc. shares.
No Form 144 notices for Lineage Cell Therapeutics, Inc. are on file.